eFFECTOR Therapeutics, Inc. is placing its bets on a breast cancer drug candidate following the failure in a mid-stage trial of tomivosertib for non-small cell lung cancer (NSCLC), an indication where some had forecast blockbuster sales. However, the company is not yet giving up on tomivosertib, which is also in early-stage development for acute myeloid leukemia (AML).
eFFECTOR's Tomiversib Flops In Lung Cancer, Hopes Rest On AML
The company still sees a potential path forward for tomivosertib in acute myeloid leukemia, where its mechanistic rationale is distinct from the one in NSCLC.
